Bioceltix

LAST NEWS

  • 2021.09.30
    Information on the stock exchange trading
  • 2021.09.10
    Economic Forum in Karpacz
  • 2021.05.25
    Bioceltix begins the next phase of research
  • 2021.05.11
    Increasing the company's share capital
  • 2021.03.10
    Dom Maklerski Banku Ochrony Środowiska S.A.

ARCHIVE ENTRIES

  • September 2021
  • May 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • May 2017
  • March 2017
  • February 2017
  • November 2016
  • October 2016
Bioceltix
  • pl
  • About the Company
  • Research and Development
  • Pharmaceutical product candidates
  • Biopharmaceuticals
  • News
  • Informations for shareholders
  • Investor relations
  • Partnership
  • Contact
  • EU co-financed projects

Home site

  • About the Company
  • Biopharmaceuticals
  • News
  • Dla akcjonariuszy
  • Dla Inwestorów
  • Partnership
  • Contact
  • EU co-financed projects
  • Privacy policy

Projects

  • Atopic dermatitis in dogs

Products

  • Kandydaci na leki
  • BCX-CM-J
  • BCX-CM-AD
  • BCX-EM

Contact with Us

Bioceltix JSC.
Bierutowska 57-59 Str., building III
52-326 Wrocław

Tel: +48 71 880 87 71

Fax: +48 71 734 55 09

office@bioceltix.com

Bioceltix
Copyright © 2023